Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.
Tentang
Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and sitravatinib, a spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Harga saat ini dari MRTX adalah $58,70 USD — turun sebesar -0,17% dalam 24 jam terakhir. Pantau kinerja harga saham Mirati Therapeutics lebih dekat di grafik.
Apa simbol saham Mirati Therapeutics?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa XNAS, saham Mirati Therapeutics diperdagangkan dengan simbol MRTX.
Berapa kapitalisasi pasar Mirati Therapeutics?▼
Hari ini Mirati Therapeutics memiliki kapitalisasi pasar sebesar 3,38B
Berapa pendapatan Mirati Therapeutics tahun lalu?▼
Pendapatan Mirati Therapeutics tahun lalu berjumlah 12,44M USD.
Berapa pendapatan bersih Mirati Therapeutics tahun lalu?▼
Pendapatan bersih MRTX untuk tahun lalu adalah -740,87M USD.
Berapa jumlah karyawan Mirati Therapeutics?▼
Per Juli 08, 2026, perusahaan memiliki 199 karyawan.
Mirati Therapeutics berada di sektor apa?▼
Mirati Therapeutics beroperasi di sektor Manufaktur.